Related Experiment Video

Updated: Jun 2, 2026

High efficiency, Site-specific Transfection of Adherent Cells with siRNA Using Microelectrode Arrays (MEA)
09:14

High efficiency, Site-specific Transfection of Adherent Cells with siRNA Using Microelectrode Arrays (MEA)

Published on: September 13, 2012

Minicells: versatile vectors for targeted drug or si/shRNA cancer therapy

Jennifer A MacDiarmid1, Himanshu Brahmbhatt

  • 1EnGeneIC Ltd, Cancer Therapeutics, Lane Cove West, Sydney, NSW 2066, Australia.

Current Opinion in Biotechnology
|May 10, 2011
PubMed

Insights

This study reviews a novel nano-cellular (minicell) delivery vehicle for cancer therapy. Minicells effectively target tumors and show no toxicity, offering potential for personalized cancer medicine.

Area of Science:

  • Oncology
  • Nanotechnology
  • Drug Delivery

Background:

  • Cancer therapy faces challenges from tumor heterogeneity, drug resistance, and drug toxicity.
  • Developing effective and safe therapeutic delivery systems is crucial for improving patient outcomes.

Purpose of the Study:

  • To review the potential of a versatile nano-cellular (minicell) delivery vehicle for cancer treatment.
  • To highlight the efficacy and safety of minicell-based therapeutics in preclinical and clinical settings.

Main Methods:

  • Minicells are engineered to carry chemotherapeutic drugs, siRNAs, or shRNAs.
  • Minicell surfaces are functionalized with bispecific antibodies for targeted tumor delivery.
  • Efficacy and toxicity were evaluated in murine xenograft models and canine cancer patients.

Main Results:

  • Minicell therapeutics demonstrated significant tumor stabilization and regression in preclinical models.
  • Case studies in canines with advanced tumors showed positive responses.
  • Repeated intravenous administration in both species exhibited no observable toxicity or immunogenicity.

Conclusions:

  • Minicell-based delivery systems offer a promising platform for effective and safe cancer therapy.
  • The technology has potential applications in personalized cancer medicine, addressing heterogeneity and resistance.
  • Further development could lead to novel therapeutic strategies with reduced side effects.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

DNA Vector-based RNA Interference to Study Gene Function in Cancer13:10

DNA Vector-based RNA Interference to Study Gene Function in Cancer

Published on: June 4, 2012

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...